A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.
Annovis Bio's Alzheimer's drug failed to significantly outperform the placebo in a midstage test, leading ANVS stock to plummet on Thursday.
Shares of Tesla (NASDAQ: TSLA), the electric car kingpin, soared 5% through 11:30 a.m. EDT Thursday, bouncing back from a post-earnings sell-off in the stock. Beginning with the obvious (and least interesting) reason: This morning, StreetInsider.com reports that analysts at Germany's DZ Bank have upgraded Tesla shares from sell to buy, and more than doubled their price target on the stock, to $750 a share. More interesting than DZ's upgrade are some comments made by Morgan Stanley analyst Adam Jonas this morning.
Yahoo Finance’s Dan Howley breaks down what to expect for Amazon’s Q2 2021 earnings report.
Prosecutors said the prototypes didn’t function and were Frankenstein monsters cobbled together from parts from other vehicles.
Long-suffering shareholders of LendingClub (NYSE: LC) got extremely good news yesterday, after the company reported blowout second-quarter earnings. Now as a hybrid digital marketplace bank, rather than a mere fintech platform, LendingClub's new business model appears to be bearing fruit in a big way. LendingClub shareholders are celebrating today.
Yahoo Finance’s Emily McCormick reports on the day's trending tickers.
Marvell Technology just reached a new high this Thursday. The daily On-Balance-Volume (OBV) line has been creeping higher since the middle of April telling us that buyers are being more aggressive. In this weekly Japanese candlestick chart of MRVL, below, we can see that prices and our favorite indicators are in gear on the upside.
Robinhood shares are now trading on the public markets.
In the race to develop COVID-19 vaccines, Novavax (NASDAQ: NVAX) seems to have gotten the most important part right. The latest clinical trial data for the NVX-CoV2373 vaccine showed 90% overall efficacy against early variants after demonstrating 96% efficacy against the original strain. Novavax is expected to file for Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in September, after which more data should be forthcoming.
(Bloomberg) -- Robinhood Markets Inc. wanted to make history with its initial public offering, and now it might -- for the wrong reason.Shares in the broker behind the meme-stock revolution fell as much as 12% below the IPO price in the company’s first trading session. That puts the stock in the running to rank as the worst debut on record among U.S. firms that raised as much cash as Robinhood or more, according to data compiled by Bloomberg.Shares rebounded and were last trading 1% lower at $37
Robinhood Markets (NASDAQ: HOOD), as it is officially named in its public debut, made headlines when it was overwhelmed with trading interest in names like GameStop (NYSE: GME) and AMC Entertainment (NYSE: AMC), and was forced to halt buying in some stocks in late January. As of 12:45 p.m. EDT, Robinhood shares were trading 9% below its opening price. The initial public offering (IPO) is raising about $2.1 billion for the online broker that is used by many retail investors.
Steve Sosnick, Interactive Brokers Chief Strategist joins the Yahoo Finance Live panel with the latest on IPO’s as Robinhood gets ready to make it debut on the Nasdaq.
Brian Sozzi, Julie Hyman, and Myles Udland dive back into earnings which include: Comcast beating estimates with a strong push from parks reopening and broadband subscribers, Merck cutting full-year guidance despite drug sales rebounding, and PayPal stock dipping after profit misses analysts’ expectations.
In this daily bar chart of SAVA, below, we can see that prices have exploded higher from a base pattern around $10. SAVA has soared above the rising 50-day moving average line. The 200-day line intersects down around $40 so when compared to the current price level we would consider SAVA extended or "overbought" at three times the level of long-term indicator.
We’re well into the Q2 earnings season and the results coming in show a strong overall performance so far. In fact, according to FactSet, if the S&P 500’s actual growth rate for the quarter hits 74.2% - as appears likely right now - it will amount to the biggest year-over-year earnings growth rate the index has displayed since Q4 2009. It’s a confidence boosting turn of events and a slightly surprising one, as noted by Oppenheimer’s Chief Investment Strategist John Stoltzfus. Stoltzfus believes
The competition between AT&T (NYSE: T) and Verizon Communications (NYSE: VZ) has favored Verizon in recent years, as AT&T invested heavily in non-5G assets. Although AT&T made costly mistakes in its non-5G ventures, it has now worked to correct those errors. The question now for investors is whether that makes AT&T stock a better choice than buying Verizon.
Advanced Micro Devices is no longer an underdog; it's a leading chip designer gobbling up market share.
While the first space race was between the US and the Soviets, the second one is fought within the US. Virgin Galactic Holdings, Inc.(NYSE:SPCE) is a prominent competitor in the commercial spaceflight race. Earlier this month, the founder Richard Branson officially made it to space, announcing regular space tourism trips to start in 2022.
Recently, Lumen Technologies' (NYSE: LUMN) management indicated a strong interest in consummating strategic asset sales to accelerate its debt reduction efforts. Earlier this month, a Bloomberg report indicated that Lumen was negotiating the possible sale of a significant part of its domestic consumer operations to Apollo Global for upwards of $5 billion. On Monday, Lumen did announce a big asset sale agreement.